Key result
18F-FDG PET and PET/CT demonstrate ~86% sensitivity for diagnosing, staging, and monitoring Ewing sarcoma.
Why the study?
The value of 18F-FDG PET and PET/CT in diagnosis, staging, restaging, and recurrence monitoring of Ewing sarcoma family of tumors was investigated due to the need for pooled diagnostic accuracy data.
Does 18F-FDG PET/CT accurately diagnose, stage, and monitor recurrence in patients with Ewing sarcoma family of tumors?
Meta-Analysis (n=524)
Does 18F-FDG PET/CT accurately diagnose, stage, and monitor recurrence in patients with Ewing sarcoma family of tumors?
Effect estimate: Sensitivity 86%, Specificity 80%
18F-FDG PET and PET/CT demonstrate high diagnostic accuracy for detecting distant metastasis and post-operative recurrence in Ewing sarcoma family of tumors.
Supports moderate FDG-PET accuracy in Ewing sarcoma; leaves open need for prospective validation before practice change.
BACKGROUND: To investigate the value of positron emission tomography (PET) and PET/computed tomography (CT) using fluorine-18-fluorodeoxyglucose (F-FDG) in the diagnosis, staging, restaging and recurrence monitoring of Ewing sarcoma family of tumors (ESFTs), a meta-analysis was performed through systematically searching PubMed, Embase, and Cochrane Central library to retrieve articles. METHODS: After screening and diluting out the articles that met inclusion criteria to be used for statistical analysis the pooled evaluation indexes including sensitivity, specificity, and diagnostic odd ratio (DOR) as well as the summary receiver operating characteristic curve (SROC) were calculated involving diagnostic data (true positive, false positive, false negative, and true negative) extracted from original studies. RESULTS: Screening determined that out of 2007, 23 studies involving a total of 524 patients were deemed viable for inclusion in the meta-analysis. The results of the analysis showed that the sensitivity and specificity were at 86% and 80%, respectively. Additionally, a satisfactory accuracy of F-FDG PET and PET/CT was observed in detecting ESFT recurrence, lung metastasis, and osseous metastasis. CONCLUSION: This meta-analysis suggests that F-FDG PET and PET/CT with an extremely high accuracy could be considered a valuable method for detecting distant metastasis and post-operational recurrence of ESFT, which might have a profound impact on the development of treatment protocols for ESFT.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2018) conducted a meta-analysis in Ewing sarcoma family of tumors (ESFTs) (n=524). 18F-FDG PET and PET/CT was evaluated on Diagnosis, staging, restaging and recurrence monitoring (Sensitivity 86%, Specificity 80%). 18F-FDG PET and PET/CT demonstrated a pooled sensitivity of 86% and specificity of 80% for the diagnosis, staging, and recurrence monitoring of Ewing sarcoma family of tumors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: